Literature DB >> 28550029

Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters.

Anne G H Niezink1, Renske A de Jong2, Christina T Muijs2, Johannes A Langendijk2, Joachim Widder2,3.   

Abstract

BACKGROUND: Despite technical developments in treatment delivery, radiation-induced lung toxicity (RILT) remains a crucial problem in thoracic radiotherapy. Clinically based RILT scores have their limitations, and more objective measures such as pulmonary functions tests (PFTs) might help to improve treatment strategies.
PURPOSE: To summarize the available evidence about the effect of dose to the lung in thoracic radiotherapy on forced expiratory volume in one second (FEV1) and diffusion capacity (DLCO) in patients with lung and esophageal cancer treated with curative intent.
MATERIAL AND METHODS: A systematic review following the PRISMA guidelines was performed, using MEDLINE and including clinical studies using (chemo)radiotherapy (CRT) or stereotactic ablative radiotherapy (SABR) for lung or CRT for esophageal cancer that reported both lung dose-volume histogram (DVH) parameters and changes in PFT results. Search terms included lung and esophageal neoplasms, respiratory function tests, and radiotherapy.
RESULTS: Fifteen studies met the inclusion criteria. Seven out of 13 studies on lung cancer reported significant declines (defined as a p value < .05) in PFT results. Both esophageal studies reported significant DLCO declines. One SABR study found a correlation between low lung-dose parameters and FEV1 decline. Relations between decline of FEV1 (three studies) or decline of DLCO (five studies), respectively, and DVH parameters were found in eight studies analyzing CRT. Furthermore, a heterogeneous range of clinical risk factors for pulmonary function changes were reported in the selected studies.
CONCLUSIONS: There is evidence that pulmonary function declines after RT in a dose-dependent manner, but solid data about lung DVH parameters predicting changes in PFT results are scarce. A major disadvantage was the wide variety of methods used, frequently lacking multivariable analyses. Studies using prospective high-quality data, analyzed with appropriate statistical methods, are needed. The Oncologist 2017;22:1257-1264 IMPLICATIONS FOR PRACTICE: Radiation-induced lung toxicity remains crucial in thoracic radiotherapy. To prevent this toxicity in the future and individualize patient treatment, objective measures of pulmonary toxicity are needed. Pulmonary function tests may provide such objective measures. This systematic review, included all available clinical studies using external beam radiotherapy for lung or esophageal cancer reporting pulmonary function combined with dose-volume histogram parameters. There is preliminary evidence that pulmonary function declines post radiotherapy in a dose-dependent manner. Data quality and analyses were generally limited. Analyses of high-quality data are therefore urgently needed to improve individualization of advanced radiation therapy. © AlphaMed Press 2017.

Entities:  

Keywords:  Dose‐volume parameters; Esophageal cancer; Lung cancer; Pulmonary function tests; Radiotherapy

Mesh:

Year:  2017        PMID: 28550029      PMCID: PMC5634763          DOI: 10.1634/theoncologist.2016-0324

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  44 in total

1.  Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer.

Authors:  Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

2.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

Review 3.  European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer.

Authors:  Dirk De Ruysscher; Corinne Faivre-Finn; Ursula Nestle; Coen W Hurkmans; Cécile Le Péchoux; Allan Price; Suresh Senan
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

4.  Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors.

Authors:  Toshio Ohashi; Atsuya Takeda; Naoyuki Shigematsu; Etsuo Kunieda; Akitoshi Ishizaka; Junichi Fukada; Hossain M Deloar; Osamu Kawaguchi; Toshiaki Takeda; Kazuhiko Takemasa; Kouichi Isobe; Atsushi Kubo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

5.  Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension.

Authors:  G Ghobadi; B Bartelds; S J van der Veen; M G Dickinson; S Brandenburg; R M F Berger; J A Langendijk; R P Coppes; P van Luijk
Journal:  Thorax       Date:  2011-12-26       Impact factor: 9.139

6.  CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?

Authors:  Tomoki Kimura; Kanji Matsuura; Yuji Murakami; Yasutoshi Hashimoto; Masahiro Kenjo; Yuko Kaneyasu; Koichi Wadasaki; Yutaka Hirokawa; Katsuhide Ito; Motoomi Okawa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-14       Impact factor: 7.038

7.  Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.

Authors:  Cinzia Ferrero; Serena Badellino; Andrea Riccardo Filippi; Luana Focaraccio; Matteo Giaj Levra; Mario Levis; Francesco Moretto; Roberto Torchio; Umberto Ricardi; Silvia Novello
Journal:  Lung Cancer       Date:  2015-06-26       Impact factor: 5.705

8.  Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: a prospective study.

Authors:  Irina Enache; Georges Noel; Mi Young Jeung; Nicolas Meyer; Monique Oswald-Mammosser; Cristina Pistea; Guy-Michel Jung; Bertrand Mennecier; Elisabeth Quoix; Anne Charloux
Journal:  Respiration       Date:  2012-11-13       Impact factor: 3.580

9.  Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer.

Authors:  Ramesh Gopal; George Starkschall; Susan L Tucker; James D Cox; Zhongxing Liao; Michael Hanus; Jason F Kelly; Craig W Stevens; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

10.  No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.

Authors:  Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

View more
  8 in total

1.  MiRNA-21 functions in ionizing radiation-induced epithelium-to-mesenchymal transition (EMT) by downregulating PTEN.

Authors:  Zheng Liu; Xin Liang; Xueping Li; Xiaodan Liu; Maoxiang Zhu; Yongqing Gu; Pingkun Zhou
Journal:  Toxicol Res (Camb)       Date:  2019-02-28       Impact factor: 3.524

2.  Carbon Monoxide Diffusing Capacity (DLCO) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III.

Authors:  Markus Stana; Brane Grambozov; Christoph Gaisberger; Josef Karner; Elvis Ruznic; Johannes Berchtold; Barbara Zellinger; Raphaela Moosbrugger; Michael Studnicka; Gerd Fastner; Felix Sedlmayer; Franz Zehentmayr
Journal:  Diagnostics (Basel)       Date:  2022-04-19

3.  A novel Approach for Non-Invasive Lung Imaging and Targeting Lung Immune Cells.

Authors:  Amlan Chakraborty; Simon G Royce; Cordelia Selomulya; Magdalena Plebanski
Journal:  Int J Mol Sci       Date:  2020-02-27       Impact factor: 5.923

4.  Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer.

Authors:  Brane Grambozov; Frank Wolf; Julia Kaiser; Romana Wass; Gerd Fastner; Christoph Gaisberger; Lukas Rettenbacher; Michael Studnicka; Christian Pirich; Felix Sedlmayer; Franz Zehentmayr
Journal:  Thorac Cancer       Date:  2019-12-19       Impact factor: 3.500

5.  The Effects of Simultaneous Pulmonary Rehabilitation during Thoracic Radiotherapy in the Treatment of Malignant Diseases.

Authors:  Myeong Geun Choi; Hyang Yi Lee; Si Yeol Song; Su Ssan Kim; Seung Hak Lee; Won Kim; Chang-Min Choi; Sei Won Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2021-02-10

6.  Long non-coding RNA MEG3 mediates the miR-149-3p/FOXP3 axis by reducing p53 ubiquitination to exert a suppressive effect on regulatory T cell differentiation and immune escape in esophageal cancer.

Authors:  Qi-Rong Xu; Jian Tang; Hong-Ying Liao; Ben-Tong Yu; Xiang-Yuan He; Yu-Zhen Zheng; Sheng Liu
Journal:  J Transl Med       Date:  2021-06-17       Impact factor: 5.531

7.  Feasibility of an outpatient-based pulmonary rehabilitation program for lung cancer patients during radiation therapy.

Authors:  Hye Joon Ahn; Jae Yong Jeon; Su Ssan Kim; Si Yeol Song; Won Kim; Sei Won Lee; A Hyun Kim; Seung Hak Lee
Journal:  Thorac Cancer       Date:  2021-06-30       Impact factor: 3.500

8.  Prospective Study of Proton Therapy for Lung Cancer Patients with Poor Lung Function or Pulmonary Fibrosis.

Authors:  Jae Myoung Noh; Hongseok Yoo; Woojin Lee; Hye Yun Park; Sun Hye Shin; Hongryull Pyo
Journal:  Cancers (Basel)       Date:  2022-03-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.